Actuate Therapeutics Inc
NASDAQ:ACTUBiotechnology
+$0.06 today
- Market cap
- $50.01M
- Beta
- 0.53
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.92
Volume 0.03M
Average 0.16M
ACTU Interest Income
Income earned on cash, deposits, and investments held by the company.
Actuate Therapeutics IncNASDAQ: ACTU
Interest Income · Q1 FY2026 · quarter ended Mar 2026
Interest income growth accelerates
Q1 FY2026 interest income of $85.27K rose 59.0% year over year, ahead of the +22.3% change in trailing-twelve-month interest income. Sequentially, it fell 38.9% from the prior quarter. Over 3 fiscal years it compounded at +120.0% a year.
Context
- Interest income increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +59.0% holds above the trailing-twelve-month pace of +22.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Income history
USD · from the income statement
- Latest · FY2025
- 287.71K USD
- Year-over-year change
- +29.4%
- 3-year CAGR
- +120.0%
| Period | Period end | Interest Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 287.71K | +29.4% |
| FY2024 | 2024-12-31 | 222.29K | -37.0% |
| FY2023 | 2023-12-31 | 352.67K | +1204.9% |
| FY2022 | 2022-12-31 | 27.03K | — |
Interest Income vs competitors
How ACTU compares with its peers on the latest reported figures
- Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +22.3% is the 2nd highest of 8, against a peer median of -34.2%.
- Over three fiscal years its annual growth of +120.0% compares with a peer median of +31.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $13.96M USD | -31.7% | +40.5% | — | |
| LTM Mar 2026 | $9M USD | +153.2% | +64.3% | — | |
| LTM Mar 2026 | $4.15M USD | -36.5% | +12.9% | — | |
| LTM Mar 2026 | $1.98M USD | -53.6% | +31.4% | 3.6% | |
| LTM Mar 2026 | $1.93M USD | -34.2% | -10.0% | 168.6% | |
| LTM Mar 2026 | CHF 1.48M CHF | -47.8% | +8.4% | — | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $723K USD | -13.6% | +128.8% | — |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $319.36K USD | +22.3% | +120.0% | — |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding ACTU) | — | -34.2% | +31.4% | 3.6% | |
Competitors are the stored peer set for ACTU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — |
| Research & Development | 16.39M | 21.71M | 18.68M | 10.29M |
| Selling, General & Admin | 3.82M | 3.27M | 6.48M | 12.2M |
| Operating Expenses | 20.21M | 24.97M | 25.16M | 22.5M |
| Depreciation & Amortization | 63.61K | 272.85K | 2.14M | 0 |
| EBITDA | (20.08M) | (24.43M) | (25.16M) | (22.21M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (20.21M) | (24.97M) | (25.16M) | (22.5M) |
| Operating Margin | — | — | — | — |
| Interest Income | 27.03K | 352.67K | 222.29K | 287.71K |
| Interest Expense | 16.2K | 43.64K | (18.72K) | 20.25K |
| Other Income / Expenses | 47.41K | 229.21K | (2.12M) | 267.46K |
| Income Before Tax | (20.16M) | (24.74M) | (27.28M) | (22.23M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 0 | 0 | 800 | 0 |
| Net Income | (20.16M) | (24.74M) | (27.29M) | (22.23M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (1.34) | (1.65) | (3.26) | (1.06) |
| EPS (Diluted) | (1.34) | (1.65) | (3.26) | (1.06) |
| Weighted Avg Shares | 15.03M | 15.03M | 19.51M | 21.02M |
| Weighted Avg Shares (Diluted) | 15.03M | 15.03M | 19.51M | 21.02M |
Actuate Therapeutics Inc
NASDAQ:ACTU
Intrinsic Alpha fair value
Locked
Current Price
$2.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.